



CSCO 4th Beijing international
MELANOMA
CONGRESS

CSCO 2018 第4届 北京黑色素瘤国际研讨会

会议日程 AGENDA

Friday, Aug24, 2018

10:00am - 10:00pm Registration; Lobby in New Yunnan Hotel Beijing

SATURDAY, AUG25, 2018

07:00am - 08:30am Registration & Breakfast

08:30am - 09:00am Welcome and Introductions

Prof. Zhan Qimin (President of Peking University Health Science Center, CHN)

Prof. Sun Yan (Cancer Hospital Chinese Academy of Medical Sciences, CHN)

Prof. Qin Shukui (Vice Chairman of Chinese Society of Clinical Oncology, CHN)

Keynote Lecture

Host: Prof. Qin Shukui (Bayi Hospital of PLA, Nanjing, CHN)

Prof. Lin Tongyu (Sun Yat-Sen University Cancer Hospital, CHN)

09:00am - 09:30am Combination therapy - what does the future hold?

Keith T. Flaherty, MD (Massachusetts General Hospital Cancer Center, USA)

09:30am - 10:00am State of the art treatments for melanoma – what is the current situation?

Georgina Long, BSc PhD MBBS FRACP

(Melanoma Institute of Australia, The University of Sydney and Royal North Shore Hospital, AUS)

10:00am – 10:10am Coffee & Tea

Session 1: Immunotherapy: checkpoint inhibitors

Host: Prof. Liang Jun (Peking University International Hospital, CHN)

Prof. Liu Jiwei (Dalian Medical University Hospital, CHN)

Prof. Wu Di (The First hospital of Jilin University, CHN)

10:10am - 10:30am Rationale for immunotherapy in melanoma

Siwen Hu-Lieskovan, MD, PhD (UCLA Medical Center, USA)

10:30am – 10:50am Biomarkers for early response to anti-PD-1 therapy

Xiaowei Xu, PhD (Hospital of University of Pennsylvania, USA)

10:50am – 11:10am Immunotherapy resistance and biomarkers for patients selection

Omid Hamid, MD (Angeles Clinic and Research Institute, Los Angeles, USA)

11:10am – 11:30am When to cease immunotherapy?

Matteo Carlino, MD, PhD (University of Sydney, Melanoma Institute of Australia, AUS)

11:30am – 12:00pm Question & Panel discussion

All attendees

MSD Satellite Meeting (Keytruda Melanoma China Launch)

Host: Prof. Qin Shukui (Bayi Hospital of PLA, Nanjing, CHN)

Prof. Guo Jun (Peking University Cancer Hospital & Institute, CHN)

- 12:10pm – 12:15pm Immunotherapy in Treating Advanced Melanoma - A New Choice Option After Treatment Failure
- 12:15pm – 12:35pm Understanding Efficacy & Safety - How I Treat My Patients using Immunotherapy
Georgina Long, BSc PhD MBBS FRACP
(Melanoma Institute of Australia, The University of Sydney and Royal North Shore Hospital, AUS)
- 12:35pm – 12:55pm Understanding Efficacy & Safety - How I Treat My Patients using Immunotherapy
Alexander Eggermont, MD, PhD (Institut de cancer ologie GustaveRoussy, FR)
- 12:55pm – 01:10pm A New Era of Melanoma Treatment in China
Guo Jun (Peking University Cancer Hospital & Institute, CHN)
- 01:10pm – 01:20pm Discussion & Q&A
Prof. Guo Jun, Zhang Xiaoshi, Wu Di and Si Lu

Session 2: Surgery Neoajuvant/adjuvant therapy

Host: Prof. Niu Xiaohui (Beijing Jishuitan hospital, CHN)

Prof. Chen Yong (Fudan University Shanghai Cancer Hospital, CHN)

Prof. Li Hang (Peking University First Hospital, CHN)

- 01:30pm - 01:50pm The role of the surgeon in the era of effective systemic therapy
Jonathan Zager, MD (H. Lee Moffitt Cancer Center and Research Institute, USA)
- 01:50pm - 02:10pm Lymph node management: SLNB vs. completion lymphadenectomy
Merrick Ross, MD (MD Anderson Cancer Center, USA)
- 02:10pm - 02:30pm New adjuvant landscape for stage III: impact on managing stage III and next steps
Alexander Eggermont, MD, PhD (Institut de cancer ologie GustaveRoussy, FR)
- 02:30pm - 02:50pm High Risk Stage Melanoma: Update of adjuvant and neoadjuvant checkpoint immunotherapy
Steven O'Day, MD (John Wayne Cancer Institute, USA)
- 02:50pm - 03:00pm Coffee & Tea

Session 3: Targeted therapy and Combinations

Host: Prof. Pan Hongming (Sir Run Shaw Hospital of Zhejiang University school of Medicine, CHN)

Prof. Zhang Xiaoshi (Sun Yat-Sen University Cancer Hospital, CHN)

Prof. Fang MeiYu (Zhejiang Cancer Hospital, CHN)

- 03:00pm - 03:20pm Updates of targeted therapy in melanoma
Axel Hauschild, MD (University Hospital Schleswig-Holstein, GER)
- 03:20pm - 03:40pm Cross-resistance of MAPK inhibitors and immunotherapy
Grant McArthur, MBBS, BMedSc, PhD, FRACP (Peter MacCallum Cancer Center, AUS)
- 03:40pm - 04:00pm New targets beyond MAPK pathway signaling
Jeffrey Sosman, MD (Northwestern University Medical Center, USA)
- 04:00pm - 04:20pm Combinations of checkpoints and TKI
Dirk Schadendorf, MD (University Hospital Essen, GER)
- 04:20pm - 04:40pm Liquid biopsy in melanoma
David Hoon, PhD (John Wayne Cancer Institute, USA)
- 04:40pm - 05:00pm Targeted therapy in China, Dabrafenib+Trametinib in Chinese population
Lu Si, MD (Peking University Cancer Hospital & Institute, CHN)
- 05:00pm - 05:10pm A phase Ib study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) combination with axitinib in patients with metastatic mucosal melanoma
Xieqiao, Yan (Peking University Cancer Hospital & Institute, CHN)
- 05:10pm - 05:50pm Question & Panel discussion
All attendees

SUNDAY, AUG26, 2018

Session 4: Immunotherapy & Topical therapy This session sponsored by Oriogene Com.

Host: Prof. Wang Baocheng (Jinan Military General Hospital , CHN)

Prof. Chi Zhihong (Peking University Cancer Hospital & Institute, CHN)

Prof. Hu Yi(The General Hospital of the People's Liberation Army, CHN)

Prof. Zou Zhengyun(Nanjing Drum Tower Hospital, CHN)

- 08:00am - 08:20am Beyond checkpoint: new targets regarding immunotherapy
Jeffrey S. Weber, MD,PhD (Langone Medical Center, New York University, USA)
- 08:20am - 08:40am Intralesional and perfusional monotherapy for regionally metastatic melanoma
Jonathan Zager, MD (H. Lee Moffitt Cancer Center and Research Institute, USA)
- 08:40am - 09:00am Combination intralesional immunotherapy – the path forward
Robert Andtbacka, MD (University of Utah, USA)
- 09:00am - 09:10am Intralesional immunotherapy: Chinese experience
Chuanliang Cui, MD (Peking University Cancer Hospital & Institute, CHN)

Session 5: Acral & mucosal melanoma forum

Host: Prof. Du Nan (the 1st affiliated Hospital of General Hospital of the People's Liberation Army, CHN)

Prof. Luo Zhiguo (Fudan University Shanghai Cancer Hospital, CHN)

Prof. Chen Jing(Wuhan Union Hospital, CHN)

- 09:10am - 09:30am Acral and mucosal melanoma: A long way to go
Jun Guo, MD, PhD (Peking University Cancer Hospital & Institute, CHN)
- 09:30am - 09:50am Advances in the treatment of advanced extracutaneous melanomas
Sapna Patel, MD (MD Anderson Cancer Center, USA)
- 09:50am - 10:10am Genomic Classification of mucosal melanoma
Richard Scolyer, MD (University of Sydney, Melanoma Institute Australia, AUS)
- 10:10am - 10:25am Genetic Aberrations in the CDK4 pathway associated with innate resistance to PD-1 blockade in acral melanoma
Yan Kong, PhD (Peking University Cancer Hospital & Institute, CHN)
- 10:25am - 10:35am Coffee & Tea

Session 6: MDT & Panel Discussion

Host: Prof. Tao Min (Cancer Hospital of Yunnan Province, CHN)

Prof. Ren Xiubao(Tianjing Cancer Hospital, CHN)

Prof. Cang Shundong(Henan Provincial People's Hospital)

Discussion Panel:

Jun Guo, MD, PhD (Peking University Cancer Hospital & Institute, CHN)

Keith T. Flaherty, MD (Massachusetts General Hospital Cancer Center, USA)

Axel Hauschild, MD (University Hospital Schleswig-Holstein, GER)

Grant McArthur, MBBS, BMedSc, PhD, FRACP (Peter MacCallum Cancer Center, AUS)

Mohamad Farid MBBS, M Med, MRCP (National Cancer Centre Singapore, SIN)

- 10:35am - 10:50am Case Discussion---Acral melanoma(case report and MDT discussion--15')
Presenter: Xu Yu (Fudan University Shanghai Cancer Hospital, CHN)
MDT Team: Liu Xin(Physician) Xu Yu(Surgeon) Shen Xuxia(Pathologist)
Wang Shengping(Radiologist) Yang Lifeng(Radiation Therapist)
- 10:50am - 11:20am Panel Discussion
- 11:20am - 11:35am Case Discussion---Mucosal melanoma(case report and MDT discussion--15')
Presenter: Mao Lili (Peking University Cancer Hospital, CHN)
MDT Team: Mao Lili(Physician) Lai Yumei(Pathologist) Guo Wei(Surgeon)
Wang Zhilong(Radiologist) Geng Jianhao(Radiation Therapist)
- 11:35am - 12:05pm Panel Discussion
- 12:05pm - 12:10pm Closing Remarks
Jun Guo, MD, PhD (Peking University Cancer Hospital, CHN)
Keith T. Flaherty, MD (Massachusetts General Hospital Cancer Center, USA)